https://www.live-feeds.com/feed/moderna-stock-soars-on-cancer-vaccine-successContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-stock-soars-on-cancer-vaccine-successhttps://www.live-feeds.com/feed/moderna-stock-soars-on-cancer-vaccine-success#u47732Tue, 25 Aug 2026 01:05:58 +0000Moderna shares jumped 177% after a Phase 3 trial for its mRNA cancer vaccine showed success in preventing melanoma from returning. The vaccine was developed in collaboration with Merck. While the stock price has surged, some analysts caution that the treatment's effectiveness may not extend to cancer types other than melanoma. This development marks a significant application of mRNA technology beyond the company's previous work on infectious diseases.Why it mattersThe vaccine targets melanoma using mRNA technology to prime the immune system. This trial follows a period of optimism re https://www.live-feeds.com/feed/moderna-stock-soars-on-cancer-vaccine-successhttps://www.live-feeds.com/feed/moderna-stock-soars-on-cancer-vaccine-success#u45641Thu, 20 Aug 2026 21:10:25 +0000Moderna's cancer vaccine, developed in partnership with Merck, has shown promise in a late-stage trial, preventing melanoma from returning. The vaccine, which uses mRNA technology, has led to a significant surge in Moderna's stock price, with gains of up to 160% this year. The trial's success has generated optimism about the potential for mRNA-based cancer treatments.Why it mattersThe cancer vaccine's success is a major breakthrough for Moderna and the field of oncology. Melanoma is a serious form of skin cancer, and current treatments have limited effectiveness. The vaccin